Profile of PANBELA THERAPEUTICS INC(NASDAQ:PBLA) stock

PANBELA THERAPEUTICS INC0.2703

NASDAQ:PBLA (9/30/2022, 7:00:03 PM)-0.09 (-24.71%)

After market: 0.269 0 (-0.48%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Biotechnology

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	08-15 2022-08-15/amc	Earnings (Next)	11-08 2022-11-08
Ins Owners	1.6%	Inst Owners	N/A
Market Cap	5.62M	Shares	20.79M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	82.22
IPO	07-29 2014-07-29

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 4 full-time employees. The company went IPO on 2014-07-29. The firm is focused on developing disruptive therapeutics for the treatment of patients with cancer. Its primary focus is on the treatment of patients with pancreatic cancer. Its lead product candidate, SBP-101, is a polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma, ovarian cancer and other tumors. The firm is conducting Phase Ia/Ib study of the safety, tolerability and pharmacokinetics of SBP-101 when administered in combination with gemcitabine and nab-paclitaxel.

Company Info

PANBELA THERAPEUTICS INC

712 Vista Blvd # 305

Waconia MINNESOTA 55387

P: 19524791196.0

CEO: Jennifer K. Simpson

Employees: 4

Website: http://www.sunbiopharma.com/

PBLA News

2 days ago - ChartmillFriday's session: gap up and gap down stocks

Let's have a look at the gap up and gap down stocks in today's session.

2 days ago - Panbela Therapeutics, Inc.Panbela Announces Pricing of Approximately $6 Million Public Offering

MINNEAPOLIS, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela” or the “Company”), a clinical stage company...

3 days ago - Panbela Therapeutics, Inc.Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...

3 days ago - Panbela Therapeutics, Inc.Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

6 days ago - ChartmillThese stocks are moving in today's session

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

PANBELA THERAPEUTICS INC (PBLA) 0.2703 -0.09 (-24.71%)

0.2703 -0.09 (-24.71%)